Herba Epimedii extraction overcome Rosiglitazone induced bone loss in diabetic rats

Diabetes mellitus patients are more prone to suffer from bone fractures. Herba Epimedii has been demonstrated to be an osteoporosis reducer in the past. However, it is yet uncertain if Herba Epimedii may protect diabetic rats from bone loss when co-administered with rosiglitazone (RSG). This study examines the impact of Herba Epimedii on bone oxidative stress and turnover markers in diabetic rats co-treated with rosiglitazone (RSG). Streptozotocin (STZ) causes diabetics. Wistar albino rats were placed into five groups, each with six rats: control (vehicle therapy), Streptozotocin (diabetes) group, Herba Epimedii group, Rosiglitazone, and Rosiglitazone +Herba Epimedii. Each medication was given by gastric gavage once a day for 35 days. Insulin, oxidative stress, and bone turnover markers were measured in the blood using ELISA assays. Insulin and osteocalcin levels were significantly higher in diabetic rats administered Herba Epimedii than in diabetic control rats. Herba Epimedii may be able to prevent diabetic osteoporosis in RSG-treated diabetic rats by enhancing osteogenesis and lowering bone oxidative stress. The utility of Herba Epimedii as an osteoporosis therapy in diabetic individuals is supported by these findings. Keywords: Herba Epimedii, Diabetes, Osteoporosis, Rosiglitazone